Scientists imagine that combining navitoclax with ruxolitinib should help those with myelofibrosis. With this trial half the folks have navitoclax and ruxolitinib. One other 50 percent have ruxolitinib in addition to a dummy drug (placebo ). have intermediate two or significant danger myelofibrosis and also have not had a JAK2 https://knoxjoswa.blog2freedom.com/26109827/an-unbiased-view-of-navitoclax